简介:AbstractForecasting the COVID-19 confirmed cases, deaths, and recoveries demands time to know the severity of the novel coronavirus. This research aims to predict all types of COVID-19 cases (verified people, deaths, and recoveries) from the deadliest 3rd wave data of the COVID-19 pandemic in Bangladesh. We used the official website of the Directorate General of Health Services as our data source. To identify and predict the upcoming trends of the COVID-19 situation of Bangladesh, we fit the Auto-Regressive Integrated Moving Average (ARIMA) model on the data from Mar. 01, 2021 to Jul. 31, 2021. The finding of the ARIMA model (forecast model) reveals that infected, deaths, and recoveries number will have experienced exponential growth in Bangladesh to October 2021. Our model reports that confirmed cases and deaths will escalate by four times, and the recoveries will improve by five times at a later point in October 2021 if the trend of the three scenarios of COVID-19 from March to July lasts. The prediction of the COVID-19 scenario for the next three months is very frightening in Bangladesh, so the strategic planner and field-level personnel need to search for suitable policies and strategies and adopt these for controlling the mass transmission of the virus.
简介: 【摘要】宋代诗人杨万里写过这样的诗句:“春花秋日冰雪,不听陈言只听天(自然之意)。”意思是大自然的景物,不能为景而写景,更不可“情不够,景来凑”,应该学会让景物说话,这样它才能为我们的文章“锦上添花”。《语文课程标准》指出,多角度地观察生活,发现生活的丰富多彩,捕捉事物的特征,力求有创意地表达。”因此,要指导学生通过大量的阅读,多角度的观察,并联系自己的生活和情感体验,发现自然、人文景物的丰富多彩,捕捉景物的特征,得到有益的启示,力求有创意的表达。要做到这一步,就得让学生在景物描写中用独到的表现手法,创造出真实面美丽的景象。初中学生已经掌了基本的叙事能力,因而,指导他们在作文中运用景物描写,有着非常重要的意义。
简介:【摘要】 目的 研究麻醉精神类药品在管理过程中实施处方登记和处方编号管理的价值。方法 选择2019年1月-2021年12月在我院应用麻醉精神类药品进行治疗的患者140例,根据用药治疗期间药品管理模式的不同将其分成对照组和观察组。对照组中70例患者采用常规模式对麻醉精神类药品实施管理;观察组中70例患者采用处方登记和处方编号模式对麻醉精神类药品实施管理。对比两组研究对象对药品管理模式的满意度、不合格处方数、不良反应、纠纷事件情况、麻醉精神类药品应用时间和疾病治疗总时间。结果 观察组研究对象对药品管理模式的满意度高于对照组,组间数据比较差异有统计学意义(P<0.05);不合格处方数、不良反应、纠纷事件例数少于对照组,组间数据比较差异有统计学意义(P<0.05);麻醉精神类药品应用时间和疾病治疗总时间短于对照组,组间数据比较差异有统计学意义(P<0.05)。结论 麻醉精神类药品在管理过程中应用处方登记和处方编号模式,可以明显减少不合格处方数和不良反应,使纠纷事件发生率降低,缩短病情治疗时间,使患者满意度得到显著提升。
简介:【摘要】 目的 研究麻醉精神类药品在管理过程中实施处方登记和处方编号管理的价值。方法 选择2019年1月-2021年12月在我院应用麻醉精神类药品进行治疗的患者140例,根据用药治疗期间药品管理模式的不同将其分成对照组和观察组。对照组中70例患者采用常规模式对麻醉精神类药品实施管理;观察组中70例患者采用处方登记和处方编号模式对麻醉精神类药品实施管理。对比两组研究对象对药品管理模式的满意度、不合格处方数、不良反应、纠纷事件情况、麻醉精神类药品应用时间和疾病治疗总时间。结果 观察组研究对象对药品管理模式的满意度高于对照组,组间数据比较差异有统计学意义(P<0.05);不合格处方数、不良反应、纠纷事件例数少于对照组,组间数据比较差异有统计学意义(P<0.05);麻醉精神类药品应用时间和疾病治疗总时间短于对照组,组间数据比较差异有统计学意义(P<0.05)。结论 麻醉精神类药品在管理过程中应用处方登记和处方编号模式,可以明显减少不合格处方数和不良反应,使纠纷事件发生率降低,缩短病情治疗时间,使患者满意度得到显著提升。
简介:AbstractThe impact of coronavirus disease 2019 (COVID-19) on endometriosis (EM) is currently unclear. Here, we aimed to describe the potential influence of COVID-19 on the pathogenesis, clinical symptoms, and treatment of EM. The cytokine storm caused by COVID-19 may induce the occurrence and progression of EM, and immunosuppression of COVID-19 may help the ectopic endometrium escape from immune clearance. Consequently, the forced social isolation and the cancelation of non-emergency medical treatment during the COVID-19 pandemic aggravate anxiety and psychological pressure, which can aggravate the symptoms related to EM and delay routine medical services.
简介:AbstractBackground:To date, there is no effective medicine to treat coronavirus disease 2019 (COVID-19), and the antiviral efficacy of arbidol in the treatment for COVID-19 remained equivocal and controversial. The purpose of this study was to evaluate the efficacy and safety of arbidol tablets in the treatment of COVID-19.Methods:This was a prospective, open-label, controlled and multicenter investigator-initiated trial involving adult patients with confirmed severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. Patients were stratified 1:2 to either standard-of-care (SOC) or SOC plus arbidol tablets (oral administration of 200 mg per time, three times a day for 14 days). The primary endpoint was negative conversion of SARS-CoV-2 within the first week. The rates and 95% confidential intervals were calculated for each variable.Results:A total of 99 patients with laboratory-confirmed SARS-CoV-2 infection were enrolled; 66 were assigned to the SOC plus arbidol tablets group, and 33 to the SOC group. The negative conversion rate of SARS-CoV-2 within the first week in patients receiving arbidol tablets was significantly higher than that of the SOC group (70.3% [45/64] vs. 42.4% [14/33]; difference of conversion rate 27.9%; 95% confidence interval [CI], 7.7%-48.1%; P = 0.008). Compared to those in the SOC group, patients receiving arbidol tablets had a shorter duration of clinical recovery (median 7.0 days vs. 12.0 days; hazard ratio [HR]: 1.877, 95% CI: 1.151-3.060, P = 0.006), symptom of fever (median 3.0 days vs. 12.0 days; HR: 18.990, 95% CI: 5.350-67.410, P < 0.001), as well as hospitalization (median 12.5 days vs. 20.0 days; P < 0.001). Moreover, the addition of arbidol tablets to SOC led to more rapid normalization of declined blood lymphocytes (median 10.0 days vs. 14.5 days; P > 0.05). The most common adverse event in the arbidol tablets group was the elevation of transaminase (5/200, 2.5%), and no one withdrew from the study due to adverse events or disease progression.Conclusions:SOC plus arbidol tablets significantly increase the negative conversion rate of SARS-CoV-2 within the first week and accelerate the recovery of COVID-19 patients. During the treatment with arbidol tablets, we find no significant serious adverse events.Trial registration:Chinese Clinical Trial Registry, NCT04260594, www.clinicaltrials.gov/ct2/show/NCT04260594?term= NCT04260594&draw=2&rank=1
简介:摘要由严重急性呼吸综合征冠状病毒2(SARS-CoV-2)引起的2019年冠状病毒疾病(COVID-19)已经在全球多个国家引起大流行,该病毒传染性强、致死率高,部分变异株在病毒传播性、致病性和免疫原性等多方面发生变化。无症状感染和有症状感染的COVID-19患者在免疫特征上存在异质性;不同年龄阶段的COVID-19患者的临床表现也不尽相同。目前无治疗COVID-19的特效药物,疫情控制需依赖新型冠状病毒疫苗的接种,如核酸疫苗、灭活疫苗、病毒载体疫苗、蛋白质疫苗等。本文通过对新型冠状病毒的变异、临床表现、治疗和疫苗等方面文献的复习,展现目前相关研究的进展。
简介:【摘要】奉贤新城09单元09A-03A地块项目G5#单体有三项不规则:1)扭转不规则,2)楼板局布不连续、3)竖向抗侧力构件不连续,另个还有效楼板宽度偏窄,特别不规则项为一项。属于超限高层。采用性能的抗震设计方法,经盈建科和迈达斯两种软件分析设计,抗震性能化目标依规范判断定义为D级。 进行了三种地震作用分析,小震(反应谱分析和弹性时程分析)计算;中震分析:(包括弹性分析和中震不屈服),大震作用计算:(动力弹塑性分析)。计算结果得出,结构各项控制指标控制在规范要求范围内,并加强了抗震构造措施,结构整体性能及构件承载力均可以达到预期性能目标。
简介:AbstractA large-scale vaccination of coronavirus disease-19 (COVID-19) in adults has been conducted for nearly a year, and there is a growing recognition that immunization for children is also essential. It has been months since emergency use of pediatric COVID-19 vaccine was approved, we reviewed the prevalence and transmission of COVID-19 in children. The prevalence of COVID-19 in children is reduced due to vaccination even in a Delta prevalent period, so an increase in the vaccination rate is needed in children. Although the precise role of children in the transmission requires more research to uncover, they likely played a significant role, according to the available literature. We also described four candidate COVID-19 vaccines for children on their safety and immunogenicity and the impact of severe acute respiratory syndrome coronavirus 2 variants on childhood vaccination. Safety issues on pediatric vaccines post-approval, like adverse events following immunization and adverse events of special interest require studies on long-term and effective regulatory mechanisms.